Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Shedding Clear all
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT01346475
View directory record Official record
Conditions
Genital Herpes
Interventions
Valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 12, 2026, 2:06 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

NCT01032837
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
100
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 12, 2026, 2:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
COVID-19 vaccines
Biological
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Miami, Florida • Vonore, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

NCT00493285
View directory record Official record
Conditions
Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 23 Months
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
30
States / cities
Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

NCT02474901
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Quadrivalent Live Attenuated Influenza Vaccine
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 25 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 12, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000
View directory record Official record
Conditions
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Interventions
aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
Biological · Radiation
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 12, 2026, 2:06 AM EDT
Completed No phase listed Observational Results available

Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

NCT01878383
View directory record Official record
Conditions
Herpes Simplex Virus
Interventions
Genexpert assay
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
12,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RSV Challenge in Healthy Adults

NCT00100373
View directory record Official record
Conditions
Respiratory Infections, Acute, Respiratory Syncytial Virus
Interventions
RSV challenge material
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Moderna COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
1,923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT00362297
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir, valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women

NCT00096694
View directory record Official record
Conditions
HIV Infections
Interventions
Levonorgestrel-releasing intrauterine device (IUD)
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Fall River, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416
View directory record Official record
Conditions
Healthy
Interventions
MEDI-559, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
75
States / cities
Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 12, 2026, 2:06 AM EDT
Withdrawn No phase listed Observational

Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

NCT01597180
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

NCT01314911
View directory record Official record
Conditions
Influenza, Human
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
44
States / cities
Chandler, Arizona • Costa Mesa, California • Garden Grove, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

NCT00345670
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Year to 9 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2008 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

NCT02484417
View directory record Official record
Conditions
Upper Respiratory Tract Infection
Interventions
RSV A2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 12, 2026, 2:06 AM EDT
Completed No phase listed Observational

HSV-2 Shedding Resolution After Acyclovir Treatment

NCT00495573
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Months to 23 Months
Enrollment
1,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
51
States / cities
Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 12, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

NCT04542993
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo, Resveratrol Placebo
Dietary Supplement
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

NCT00002373
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Maribavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:06 AM EDT